tiprankstipranks
Advertisement
Advertisement

PHAR Stock Latest News

3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 5/8/2026
Market News3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 5/8/2026
8d ago
IVA
ATAI
Pharming price target lowered to $40 from $41 at Oppenheimer
PremiumThe Fly
Pharming price target lowered to $40 from $41 at Oppenheimer
9d ago
PHAR
Pharming reports Q1 EPS 1c, consensus 0c
PremiumThe Fly
Pharming reports Q1 EPS 1c, consensus 0c
10d ago
PHAR
Pharming sees FY26 revenue $405M-$425M, consensus $411.9M
PremiumThe Fly
Pharming sees FY26 revenue $405M-$425M, consensus $411.9M
10d ago
PHAR
Pharming Posts Mixed Q1 2026 as Joenja® Growth Offsets RUCONEST® Decline and Global Label Expansion Advances
PremiumCompany Announcements
Pharming Posts Mixed Q1 2026 as Joenja® Growth Offsets RUCONEST® Decline and Global Label Expansion Advances
10d ago
6K
PHAR
Pharming Group Showcases New Leniolisib Data and Expands Immunology Focus at CIS 2026
PremiumCompany AnnouncementsPharming Group Showcases New Leniolisib Data and Expands Immunology Focus at CIS 2026
10d ago
6K
PHAR
Pharming Group Sets May 28, 2026 AGM With Key Governance and Capital Measures on Agenda
Premium
Company Announcements
Pharming Group Sets May 28, 2026 AGM With Key Governance and Capital Measures on Agenda
1M ago
6K
PHAR
Pharming initiated with a Buy at Canaccord on growth potential
Premium
The Fly
Pharming initiated with a Buy at Canaccord on growth potential
1M ago
PHAR
Pharming initiated with a Buy at Canaccord
PremiumThe Fly
Pharming initiated with a Buy at Canaccord
1M ago
PHAR
Pharming Group Files 2025 Annual Report and Form 20-F
PremiumCompany Announcements
Pharming Group Files 2025 Annual Report and Form 20-F
1M ago
6K
PHAR
Pharming Group Wins Positive EMA Panel Backing for Joenja in Rare APDS
PremiumCompany Announcements
Pharming Group Wins Positive EMA Panel Backing for Joenja in Rare APDS
2M ago
6K
PHAR
Pharming announces approval of Joenja in Japan for patients aged 4 years and old
PremiumThe Fly
Pharming announces approval of Joenja in Japan for patients aged 4 years and old
2M ago
PHAR
Pharming Group Wins Landmark Japan Approval for Joenja in Pediatric and Adult APDS
PremiumCompany AnnouncementsPharming Group Wins Landmark Japan Approval for Joenja in Pediatric and Adult APDS
2M ago
6K
PHAR
Pharming price target lowered to $41 from $42 at Oppenheimer
Premium
The Fly
Pharming price target lowered to $41 from $42 at Oppenheimer
2M ago
PHAR
Pharming: Solid Execution, Resilient Revenue, and Joenja Growth Support Buy Rating Ahead of Key Leniolisib Catalysts
Premium
Ratings
Pharming: Solid Execution, Resilient Revenue, and Joenja Growth Support Buy Rating Ahead of Key Leniolisib Catalysts
2M ago
PHAR
Pharming Group Posts Strong 2025 Growth, Turns Profitable and Lifts 2026 Outlook
PremiumCompany Announcements
Pharming Group Posts Strong 2025 Growth, Turns Profitable and Lifts 2026 Outlook
2M ago
6K
PHAR
PHAR Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
PHAR Upcoming Earnings Report: What to Expect?
2M ago
PHAR
Pharming Group Sets 2026 Guidance and Showcases Rare Disease Pipeline at Investor Day
PremiumCompany Announcements
Pharming Group Sets 2026 Guidance and Showcases Rare Disease Pipeline at Investor Day
3M ago
6K
PHAR
Morning Movers: Disney dips following fourth quarter earnings
PremiumThe Fly
Morning Movers: Disney dips following fourth quarter earnings
3M ago
DIS
DVN
Pharming to host virtual investor day
PremiumThe FlyPharming to host virtual investor day
3M ago
PHAR
Pharming receives CRL from U.S. FDA for sNDA for Joenja
Premium
The Fly
Pharming receives CRL from U.S. FDA for sNDA for Joenja
3M ago
PHAR
FDA Calendar: These Are the Remaining Drug Approvals Anticipated This Month
Premium
Market News
FDA Calendar: These Are the Remaining Drug Approvals Anticipated This Month
4M ago
AQST
IRON

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >